BIO89-100: Clinical Trials

4 completed, 1 recruiting. 3 Phase 2, 2 Phase 1, 1 Phase 3.

By phase and status

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis) Pegozafermin, Placebo - Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis	Phase 3	Recruiting	Hoffmann-La Roche	1350	2024-03-13	2026-10-23
PK Study of Liquid Formulation of BIO89-100 in Subjects With NASH With Compensation Cirrhosis BIO89-100 - NASH - Nonalcoholic Steatohepatitis	Phase 1	Completed	89bio, Inc.	8	2021-08-16	2022-03-02
Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH) BIO89-100, Placebo - NASH - Nonalcoholic Steatohepatitis	Phase 2	Completed	89bio, Inc.	222	2021-06-04	2026-01-06
Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe Hypertriglyceridemia Pegozafermin, Placebo - Severe Hypertriglyceridemia	Phase 2	Completed	89bio, Inc.	86	2020-09-01	2024-07-25
A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH Pegozafermin, Placebo - NASH	Phase 1 / Phase 2	Completed	89bio, Inc.	101	2019-07-29	2024-04-02